News

The ALPHAMEDIX-02 trial showed promising results for 212Pb-DOTAMTATE in previously treated gastroenteropancreatic neuroendocrine tumors.

New trial results reveal capivasertib enhances survival in advanced prostate cancer, offering hope for patients with PTEN deficiency.

TUB-040 shows over 50% response rates in platinum-resistant ovarian cancer, highlighting its potential as a promising treatment option.

Gedatolisib enhances progression-free survival in advanced breast cancer patients, showcasing significant benefits when combined with fulvestrant and palbociclib.

New trial data reveals T-DXd plus THP significantly improves pathologic complete response rates in high-risk HER2-positive early breast cancer patients.

A phase 2 trial yielded encouraging results for pembrolizumab plus lenvatinib in uveal melanoma, showing promising progression-free survival rates.

Sacituzumab tirumotecan significantly improves progression-free survival in HR+/HER2– breast cancer compared with traditional chemotherapy.

The SKYSCRAPER-03 trial showed that consolidation tiragolumab plus atezolizumab does not improve progression-free survival in advanced lung cancer compared to durvalumab.

Invikafusp alfa shows promising antitumor activity in TMB-H and MSI-H tumors resistant to immunotherapy, offering new hope for patients.

New trial data reveals T-DXd significantly improves disease-free survival in high-risk HER2-positive breast cancer patients compared to T-DM1, offering hope for better outcomes.

New findings from the CheckMate 238 trial highlight nivolumab's superior long-term efficacy over ipilimumab in treating advanced melanoma.

New findings reveal pembrolizumab combined with paclitaxel enhances survival rates in patients with platinum-resistant recurrent ovarian cancer.

Tarlatamab-dlle shows significant overall survival benefits over chemotherapy in small cell lung cancer, even in platinum-resistant cases.

BNT111 combined with cemiplimab shows promising efficacy in treating PD-(L)1-relapsed melanoma, achieving significant response rates and manageable safety profiles.

The COMPETE trial reveals ITM-11 significantly improves progression-free survival and overall response rates in GEP-NET patients compared with everolimus.

Tarlatamab combined with frontline chemoimmunotherapy shows promising safety and efficacy in extensive-stage small cell lung cancer patients.

XTR008 therapy shows significant benefits in treating GEP-NETs, enhancing survival rates and quality of life compared to octreotide LAR.

Giredestrant combined with everolimus significantly enhances progression-free survival in advanced ER-positive breast cancer, offering a promising new treatment option.

Fruquintinib plus sintilimab significantly enhances progression-free survival in advanced renal cell carcinoma, offering a promising second-line treatment option.

Pimicotinib shows promising long-term efficacy in treating tenosynovial giant cell tumor, achieving high response rates and durable outcomes in patients.

Regorafenib and nivolumab show promising results in advanced gastric cancer, offering improved response rates and quality of life compared to chemotherapy.

Combination therapy of osimertinib and chemotherapy significantly enhances overall survival in patients with EGFR-mutated advanced lung cancer, surpassing monotherapy outcomes.

Combining local consolidative therapy with osimertinib enhances progression-free survival in metastatic EGFR-mutant non-small cell lung cancer patients.

Ribociclib combined with aromatase inhibitors significantly enhances invasive disease-free survival in early breast cancer, offering lasting benefits beyond treatment.

Abemaciclib plus endocrine therapy significantly improves overall survival in high-risk early breast cancer, reducing death risk by 15.8% compared to endocrine therapy alone.

Alectinib shows promising long-term survival benefits over crizotinib in advanced ALK-positive lung cancer, highlighting significant clinical advancements.

Patients with metastatic hormone-sensitive prostate cancer report stable health-related quality of life while receiving niraparib and abiraterone acetate in the AMPLITUDE trial.

Lenvatinib combined with pembrolizumab and chemotherapy shows no significant survival benefit over pembrolizumab plus chemotherapy in metastatic esophageal cancer.